MEDIMMUNE, LLC. for MEDIMMUNE LLC
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 2055/Pub. L. No. 112-74 - Consolidated Appropriations Act, 2012, provisions relating to funding for Health and Human Services H.R. 2405/S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization, provisions relating to pandemic influenza vaccine development H.R. 4274 - BPCA and PREA Reauthorization Act of 2012 H.R. 2679 - Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early Reauthorization Act, provisions relating to patient safety study and report Issues related to development of legislation reauthorizing the Prescription Drug User Fee Act (PDUFA), including issues relating to approval of biologics, pediatric research incentives, supply chain integrity, drug shortages, and antibiotic incentives; CDC Burden of Disease Study on Respiratory Syncytial Virus (RSV), including RSV prophylaxis; implementation of H.R. 3590/Pub. L. No. 111-148, the Patient Protection and Affordable Care Act; reimbursement of vaccines and related services; Medicaid coverage and reimbursement; biologics data exclusivity; and, debt and deficit reduction proposals on Medicaid federal funding, Medicaid rebates, and Medicare Part D rebates
Foreign entity interest: As the ultimate parent of MedImmune, LLC, AstraZeneca PLC has interests in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN RANDALL BUCKLEY | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.